From decades' tuberculosis (TB) affecting individual and a huge number of people die every year.
need for new TB drug regimens and rapid DST is intuiting globally. In future, more research with a focus on MDR and TB is required to avoid and counteract its associated complications.
Introduction
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis, is notorious for its lethality to humans 1, 21, 2 . It causes ill-health among millions of people each year and ranks as the second leading cause of death from an infectious disease worldwide. The latest estimates included in this report are that there were 8.6 million new TB cases in 2012 and 1.3 million TB deaths 3 3 .
Tuberculosis is the major infectious disease killing nearly two million people, mostly in developing countries, every year. The increasing incidence of Mycobacterium tuberculosis strains to the most cost effective anti-TB drugs is the major factor contributing to the current TB epidemic. Drug-resistant strains have involved mainly due to incomplete or improper treatment of TB patients. The resistance of Mycobacterium tuberculosis to anti-TB drugs is caused by a chromosomal mutation in encoding drug targets 44 .
TB organisms that are resistant to the antibiotics used in its treatment are widespread and occur in all countries surveyed. Drug resistance emerges as a result of inadequate treatment, and once TB organisms acquire resistance they can spread from person to anyone in the same way as drugsensitive TB 55 . The development of drug resistance by MTB is a major concern. Drug-resistant MTB strains were first recognized soon after the introduction of streptomycin in 1944, and subsequently, resistance to other TB medications was demonstrated. Spontaneous mutations that impart drug resistance to MTB occur at predictable rates 66 . Resistant strains are perpetuated by inappropriate treatment inadequate therapeutic regimen, poor patient compliance due to intolerable adverse drug effects, or treatment default because of inadequate support from local TB services 7-97-9 .
The proportion of TB cases with drug-resistance: about 3. and rifampicin (i.e. MDR-TB) as well as any fluoroquinolone and any of the second-line anti-TB injectable drugs (amikacin, kanamycin or capreomycin) 55 . Even more ominous are reports of XDR-MTB strains that also demonstrate in vitro resistance to other second-line drugs, including aminoglycosides, cyclic polypeptides, fluoroquinolones, thioamides, serine analogs, and salicylic acid derivatives 10, 1110, 11 .
Treatment needs to be continued for a minimum of 20 months with four effective drugs, with the discontinuation of the injectable medication at the end of 8 months of therapy if there is a good clinical response to the intensive phase of treatment 1212 . If drug resistance or side effects preclude inclusion of one or more of these drugs, then, in descending order of preference, para-amino salicylate or group 5 antibiotics are recommended to provide a minimum of four effective drugs 1313 . The long treatment courses are expensive and difficult to tolerate. In a population of rural Bangladeshi HIV-negative patients with pulmonary MDR-TB, without extensive additional resistance and who were not previously treated with second-line drugs, a 9-month regimen that include gatifloxacin, pyrazinamide, ethambutol, and clofazimine, and included an initial intensive 4-month phase that also included treatment with kanamycin, prothionamide, and high-dose H, resulted in a relapse-free cure rate of almost 88% with a reasonable rate of adverse effects.
Outcomes were not as good in patients treated with an ofloxacin based regimen as in the gatifloxacin-treated group 1414 . This study suggests that some patients with MDR-TB may be treated successfully with a shorter regimen than currently recommended by WHO 1215 . Figure 1 illustrates various organs/systems effects the pulmonary tuberculosis and mechanism involved in MDR.
Drug-resistant Tuberculosis
The current MDR-TB epidemic is the result of decades of neglect for an important infectious disease, lack of resources for national TB control programs, poor case detection and inadequate/inappropriate therapy in high-burden countries. Initial outbreaks of MDR-TB in developed countries were associated with very high mortality rates both in HIV-negative and Overall, the last decade has been associated with the most encouraging advances in TB therapeutics since the 1960s, but these breakthroughs have still to impact on the stubbornly high global burden of TB disease. Long-term investment, political commitment, and scientific
Endeavor will be crucial to ensure that progress is sustained and the benefits of recent advances reach those in the greatest need 1617 . With the continuing rise in the occurrence of drug-resistant strains of bacteria, new approaches to combating infections caused by these bacteria are desperately needed, particularly for Gram-negative bacteria. The one drug-one target model has 
Epidemiology of drug-resistant TB

Treatment of drug resistant TB
Treatment of MDR-TB is more complicated and longer than treatment of TB with no resistance. Table 1 .
The development of MDR-TB can be caused by a treatment that is inadequate, given the drug susceptibility pattern of the MTB strain. The information can be used to advocate the need for adequate treatment of patients, based on drug resistance profiles. Few cohort studies provided information on treatment regimens and drug resistance profiles before treatment and at failure or with multidrug-resistant tuberculosis who are cured is estimated to be no more than 69%, even when treated for more than 18 months with directly observed treatment 23, 2424, 43 .
Updated guidelines now recommend that 4 or more drugs with limited or highly probable effectiveness against TB should be included in treatment regimens. The selection of TB drugs is structured such that treatment options proceed from group 1 through to group 5. countries. An injectable agent should be given for at least six months, and the whole treatment duration is minimum 18 months beyond sputum conversion. WHO advises that injectable drugs in the treatment of XDR-TB to be continued for the extended duration of 12 months or possibly the whole treatment 1329 . Currently, the most potent drug in group 5 is linezolid, and it should thus always be included in XDR-TB. The Recent prospective trial has shown that Linezolid is effective for achieving culture conversion among patients with treatment-refractory XDR-TB.
Linezolid added to the regimen of patients failing standard XDR-TB treatment has been demonstrated to improve culture conversion, but longer-term outcomes are unknown, and cost and toxicity are major concerns 29,3030, 31 .
Mechanism of resistance
A drug resistance mechanism in MTB is crucial for the development of rapid methods for drug resistance detection and new anti-TB drugs to treat MDR-TB/XDR-TB patients 4 . The everincreasing drug use in response to growing TB incidences has resulted in a steady evolution of M. Mutations are situated within rpoAandrpo C, encodingα-and β'-subunits of the RNA polymerase, respectively, and alleviate the fitness cost associated with resistance mutations in rpoB, the β-subunit of the RNA polymerase and target of Rifampicin. Drug-resistant TB can be "acquired" de novo during treatment, or it can occur through the transmission of already resistant strains; the latter being referred to as "primary resistance." Primary resistance poses a particular challenge as less than 20% of the estimated MDR-TB cases in the world are believed to be properly diagnosed, mainly due to the lack of appropriate laboratory infrastructure in low-income areas that bear the highest disease burden 3435 . Drug-resistant TB has microbial, clinical, and programmatic causes.
From a microbiological perspective, the resistance is caused by a genetic mutation that makes a drug ineffective against the mutant bacilli. An inadequate or poorly administered treatment regimen allows drug-resistant mutants to become the dominant strain in a patient infected with TB 3536 .
Drug-resistant TB prevention and control
The overarching goal of the Stop TB Strategy is to achieve 2015 global targets for reductions in the burden of disease caused by TB. The target set within the United Nations Millennium Development Goals (MDGs) is that TB incidence should be falling by 2015. Besides incidence, 
Fluoroquinolone
Fluoroquinolones are broad-spectrum antimicrobial drugs that target DNA gyrase. Several members of this class have been used as second-line drugs for the treatment of MDR-TB 2443 . Due to their excellent oral bioavailability, bactericidal activity against M. tuberculosis, lack of crossresistance with existing anti-TB drugs and favorable safety and tolerability profile, they have been employed off-label against MDR-TB and are now regarded as cornerstone agents for this disease 88 .
I. Moxifloxacin
Study Investigated from John Hopkins University replacement of ethambutol or isoniazid with moxifloxacin or gatifloxacin in the first-line regimen has the potential to improve treatment.
Replacement of ethambutol with moxifloxacin or gatifloxacin, each at 400 mg, is further supported by the results of three recent Phase II trials. They described greater culture conversion with moxifloxacin at 8 weeks and shorter time to culture conversion with moxifloxacin during the first 2 months 16, 2417, 43 . The technique of examining EBA has also been used to study moxifloxacin. Two moxifloxacin EBA studies have demonstrated that moxifloxacin has EBA superior to that of rifampin and perhaps comparable to that of isoniazid 4144 . A chemical structure of moxifloxacin is shown in Figure 3 .
II. Gatifloxacin
The OFLOTUB trial shows two phase 3 trials of shorter duration first-line tuberculosis treatment have now completed patient enrolment and treatment and replaced Ethambutol with gatifloxacin in a four-month regimen 4242 . Newer generation fluoroquinolones significantly improve cure or treatment completion among XDR-TB patients. Among predominantly second-line treatmentnaïve MDR-TB patients, high relapse-free cure rates with good tolerance have been achieved by the inclusion of gatifloxacin 400-800 mg once daily for at least nine months 4345 . A chemical structure of gatifloxacin is shown in Figure 4 .
Oxazolidinone
The oxazolidinones exert their anti-TB activity by inhibiting protein synthesis through a novel mechanism by blocking the formation of the ribosomal initiation complex 8, 168, 17 .
I. Linezolid
Linezolid is the first oxazolidinone antimicrobial agent 24, 4443, 46 
II. PNU 100480 (Sutezolid)
It is classified in oxazolidinones with current investigations in Phase I and more potent activity against Mycobacterium tuberculosis than LZD which is the only currently marketed oxazolidinone 4446 . A chemical structure of PNU 100480 is shown in Figure 6 . The anti-TB activity of PNU-100480 was first reported in1996.Recent experiments in the murine model show it to be more active than linezolid even when serum concentrations are considerably lower. A long-term experiment demonstrated that the addition of PNU-100480 at 160 mg/kg shortened the duration of treatment necessary to prevent relapse, suggesting that PNU-100480 has sterilizing activity that could improve the treatment of drug-susceptible as well as drug-resistant TB 88 .
Diarylquinoline I. TMC-207(Bedaquiline)
TMC207 (formerly R207910) is a diarylquinoline compound with a new mechanism of action by inhibiting mycobacterial adenosine triphosphate synthase 44, 4546, 47 . A chemical structure of TMC207 is shown in Figure 7 . The target of TMC207 relied on sequence analysis of a single mutant of MTB, and two mutants of M. smegma is that were resistant to the drug and binding of 
Nitroimidazole
The anti-TB effect of this class was identified in the 1990s and is principally due to inhibition of mycolic acid synthesis in the mycobacterial cell wall 1617 . Currently, two nitroimidazoles are in clinical development. These are the nitroimidazole-oxazine PA824, which is being developed by the TB Alliance, and the dihydroimidazole-oxazole OPC67683, which is being developed by Otsuka Pharmaceutical 4144 .
I. OPC-67683 (Delamanid)
OPC-67683 is a nitroimidazole-oxazole developed after members of the class were identified in a screen for mycolic acid synthesis inhibitors. Like the related nitroimidazole-oxazine, PA-824, it appears to undergo reductive nitro activation and inhibits ketomycolic acid synthesis as at least one of its mechanisms of action 88 . A chemical structure of OPC-67683 is shown in Figure 8 .
OPC-67683 is a nitroimidazole-oxazole with cross-resistance to PA-824 without cross-resistance to current anti-TB drugs. It is more potent than PA-824 in vitro (4-16 times) and in vivo with a MIC range of 0.006-0.024 g/mL and minimal bactericidal dose which resulted in a 2 log 10 reduction in CFU of 2.5 mg/kg in mice, compared with 50 mg/kg for PA-824 in a similar model 4446 . A Phase III study of demand in MDR-TB is now underway with primary end-points based on time to sputum culture conversion in the first six months and secondary endpoints based on the durability of culture conversion out to 30 months 1617 .
II. PA-824
PA-824 is a nitroimidazole that has sterilizing activity against drug-susceptible and drug resistant TB and both active and dormant organisms induced in the hypoxic condition in vitro. The MIC of PA-824 is 0.015-0.25 mg/ml 44 46 . A chemical structure of PA-824 is shown in Figure 9 . PA-824 has now entered phase 2 trials, the advantage that patients with multidrug-resistant tuberculosis can be included into the same recruitment process as those with treatment-sensitive tuberculosis 4050 .
PA-824 demonstrates dose-dependent bactericidal and sterilizing activity in a murine model of TB. At a daily dose of 100 mg/kg in mice, it has a bactericidal activity which approaches that of Because the TL-1 enzyme is absent in eukaryotic cells, it is an attractive target for antibiotic development. Despite the ubiquity of TL-1 in bacteria, capuramycin and its analogs, including SQ641, are remarkably specific for Mycobacteria and certain Gram-positive bacteria, making it a promising candidate for a future regime 43 .
Benzothiozinones (BZT043)
A new class of anti-TB agent is called benzothiazinones. 
Imidazopyridine
Q203 is an optimized compound made from imidazopyridines, a new class of drugs that inhibit mycobacterial growth by blocking the respiratory cytochrome bc1 complex essential to maintain the proton gradient and ATP synthesis. Although the drug has a similar target as aquiline, it inhibits ATP synthesis more potently in both aerobic and hypoxic conditions. It is active against multidrug-resistant and extensively drug-resistant isolates of M. Tuberculosis from human beings, and data from mice models show a 100-1000-fold reduction of colony-forming units and a blocking of granuloma formation 4050 .
Riminophenazines Phenoxazine and asymmetrical riminophenazine series
Riminophenazinesexemplified by clofazimine, originally a dye shows potential to shorten treatment of multidrug-resistant tuberculosis, but skin coloration due to accumulation in fatty tissue and organs is a major side-effect. To reduce discoloration, TBI-166 was selected from 69 riminophenazine derivatives and first preclinical data suggests that it has retained the same antimycobacterial properties 4851 .
Future prospective of the new advances of anti-TB drugs
The mostimportant challenge in TB drug development is the difficulty in identifying new compounds with activity against M. tuberculosis. Regimens against TB should kill both the rapidly growing mycobacteria and the persisting mycobacteria in lesions [42] . New Table 2 ) [8] . Development of new medicines is a complex, lengthy, and expensive process, involving a series of stages (discovery, lead identification, and lead optimization), ultimately leading to preclinical development 3940 .
The emergence of MDR-and XDR-TB has spurred interest in the development of new drugs.
Recently, the first report of phase 2 clinical trial of TMC207 for the treatment of MDR-TB has been published. Adding TMC207 to standard therapy for MDR-TB reduced the time to conversion to a negative sputum culture, as compared with placebo. TMC207, a first-in-class diarylquinoline, has a unique mechanism of action targeting the c subunit of adenosine triphosphate synthase and exhibits a long half-life. TMC207 plus rifapentine plus PZA gave once weekly was more active than the current standard regimen of RMP plus INH plus PZA given five times per week in murine TB, suggesting that it has the potential to be used to develop a fully intermittent once-weekly regimen.PA-824 is a novel nitroimidazole-oxazine, inhibits mycolic acid and protein biosynthesis and kills non-replicating MTB as well.PA-824 Enhances bactericidal activity of RMP and PZA in a murine model of TB. The combination of PA-824, moxifloxacin, and PZA cured mice more rapidly than the first-line regimen of RMP, INH and PZA in a murine model of TB, implying the potential to shorten the duration of TB treatment.
Other imidazole-oxazole, diamine, and pyrrole compounds are being investigated in clinical phase 1 or 2 drug trials as well, yet none of the compounds will have passed phase 3 to be available before the year 2011 77 .
Conclusions
The emergence of MDR-TB and XDR-TB, the need for new TB drug regimens and rapid DST is intuiting globally. The prospect of new TB regimens is exciting because patients have had to rely on a single lengthy treatment option for decades. New DST assays to detect resistance can be Figure 1 Organs/System effects the pulmonary tuberculosis and mechanism involved in MDR. 
